{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:56:31Z","timestamp":1790758591635,"version":"4.1.0"},"reference-count":11,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To examine prostate cancer (\n                      <jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>\n                      a) incidence and mortality by arm in the randomized Prostate, Lung, Colorectal and Ovarian (\n                      <jats:styled-content style=\"fixed-case\">PLCO<\/jats:styled-content>\n                      ) cancer screening trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients aged 55\u201374 years at 10 screening centres were randomized between 1993 and 2001 to an intervention or usual care arm. Patients in the intervention arm received six annual prostate\u2010specific antigen (\n                      <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                      ) tests and four annual digital rectal examinations. The patients were followed for\n                      <jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>\n                      a incidence and for mortality via active follow\u2010up processes and by linkage to state cancer registries and the National Death Index. For cancers identified through active follow\u2010up, trial abstractors recorded the mode of diagnosis (screen\u2010detected, symptomatic, other).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 38 340 patients were randomized to the intervention arm and 38 343 to a usual care arm. The median follow\u2010up for mortality was 16.9 (intervention) and 16.7 years (usual care). There were 333 (intervention) and 352 (usual care)\n                      <jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>\n                      a cancer deaths, giving rates (per 10 000 person\u2010years) of 5.5 and 5.9, respectively, and a rate ratio (\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      ) of 0.93 (95% confidence interval [\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      ] 0.81\u20131.08;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.38). The\n                      <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                      for overall\n                      <jats:styled-content style=\"fixed-case\">PC<\/jats:styled-content>\n                      a incidence was 1.05 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      1.01\u20131.09). The RRs by Gleason category were 1.17 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      1.11\u20131.23) for Gleason 2\u20136, 1.00 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      0.93\u20131.07) for Gleason 7 and 0.89 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      0.80\u20130.99) for Gleason 8\u201310 disease. By mode of detection, during the trial's screening phase, 13% of intervention arm vs 27% of usual care arm cases were symptomatic; post\u2010screening, these percentages were 18% in each arm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>After almost 17 years of median follow\u2010up, there was no significant reduction in PCa mortality in the intervention compared with the usual care arm. There was a significant increase in Gleason 2\u20136 disease and a significant reduction in Gleason 8\u201310 disease in the intervention compared with the usual care arm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.14580","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T00:53:21Z","timestamp":1538787201000},"page":"854-860","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Extended follow\u2010up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial"],"prefix":"10.1111","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0350-3282","authenticated-orcid":false,"given":"Paul F.","family":"Pinsky","sequence":"first","affiliation":[{"name":"Division of Cancer Prevention National Cancer Institute NIH Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-1048","authenticated-orcid":false,"given":"Eric","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention National Cancer Institute NIH Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Prorok","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention National Cancer Institute NIH Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Grubb","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina Charleston SC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[{"name":"University of Colorado Health Sciences Denver CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Andriole","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810696"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810084"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr500"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60525-0"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30474"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0154"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7327"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.10.004"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774510374091"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.007"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12212"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.14580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.14580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:52:23Z","timestamp":1761742343000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.14580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/bju.14580"],"URL":"https:\/\/doi.org\/10.1111\/bju.14580","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]},"assertion":[{"value":"2018-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}